Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“A metastatic gastric cancer patient with rapid progression under chemotherapy.
Tissue vs. liquid NGS.
Liquid biopsy shows:
- High ctDNA (52%) with multiple low VAF alterations
(MAP2K1, NF1, BRAF non-V600, FGFR2, BRCA1 rearrangement)
Not seen in tissue. Likely chemotherapy-selected resistant subclones.
So the question is:
- Can we target every mutation?
- Or are these just survival strategies?
This is not a mutation list – it’s an evolution map.
Are we treating the tumor, or chasing its evolution?”
Other articles featuring Ahmet Dirican on OncoDaily.